Loading
A phase 2 trial of Nivolumab, Relatlimab + nivolumab in melanoma, run by Bristol-Myers Squibb, active and no longer recruiting.
A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations is a phase 2 interventional study registered as NCT06101134 by Bristol-Myers Squibb, with 100 participants enrolled, started 2023-11-06 and due to reach its primary completion in 2025-04-10. Interventions recorded: relatlimab+nivolumab, relatlimab+nivolumab+rHuPH20, nivolumab, nivolumab+rHuPH20. Conditions listed: Melanoma. Results were posted on ClinicalTrials.gov in 2026; the figures recorded here are the registry's, not a publication's.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
100 enrolled.
95% CI 62.4 to 89.4; Figures from the ClinicalTrials.gov results section (first posted 2026-04-09), not from a publication · 95% CI 55.9 to 83.0
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Percentage of Evaluable Participants That Prefer SC Route of Administration Using the Patient Experience and Preference Questionnaire (PEPQ) (Question 7) After Cycle 4 Day 1 Doseprimary | Cohort 1: Metastatic Melanoma | 41 | 78% | - | - | link |
| Cohort 2: Resected Melanoma | 48 | 70.8% |
Shares Relatlimab + nivolumab, Bristol Myers Squibb, Nivolumab, Melanoma.
Shares Bristol Myers Squibb, Nivolumab, Immune checkpoint inhibitors.
Shares Relatlimab + nivolumab, Nivolumab, Melanoma, Immune checkpoint inhibitors.
Shares Bristol Myers Squibb, Nivolumab, Immune checkpoint inhibitors.
Shares Bristol Myers Squibb, Nivolumab, Melanoma, Immune checkpoint inhibitors.
Shares Bristol Myers Squibb, Nivolumab, Immune checkpoint inhibitors.
Shares Bristol Myers Squibb, Nivolumab, Immune checkpoint inhibitors.
Shares Bristol Myers Squibb, Nivolumab, Immune checkpoint inhibitors.